Kolexia
Gardembas Martine Médecine générale
Gardembas Martine
Médecine générale
Hôpital Larrey Angers
Angers, France
100 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémie myéloïde chronique BCR-ABL positive Leucémie myéloïde Leucémies Leucémie myéloïde en phase chronique Neutropénie Lymphomes Thrombopénie Récidive tumorale locale Épanchement pleural

Collaborateurs

Voir plus
Nicolini Franck
Nicolini Franck
Centre Léon-Bérard, Lyon, France
Rousselot Philippe
Rousselot Philippe
Hôpital Saint-Louis, Paris, France
Mahon Francois-Xavier
Mahon Francois-Xavier
Institut Bergonié, Bordeaux, France
Legros Laurence
Legros Laurence
Hôpital Paul Brousse, Villejuif, France

Industries

Voir plus
Novartis
2 collaboration(s)
Dernière en 2023
{{person.topindus2.name}}
{{person.topindus2.tot}} collaboration(s)
Dernière en {{person.topindus2.last}}
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Characteristics, Outcomes, Tfr Rates in Young Adults with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era: A French Observational Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Hodgkin lymphoma and female fertility: a multicenter study in women treated with doxorubicin, bleomycin, vinblastine, and dacarbazine.
Blood advances   31 juillet 2023
Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
The Journal of allergy and clinical immunology   28 juin 2023
Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment-free remission period after imatinib discontinuation: Results of the French Nilo post-STIM study.
British journal of haematology   02 avril 2023
Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial.
Haematologica   01 décembre 2022
Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia.
Pharmaceutics   12 août 2022
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
British journal of haematology   30 juin 2021
Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial.
Leukemia   22 janvier 2021
ACTIW: Candidate Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors in Chronic Phase-chronic Myelogenous Leukemia Patients in CCR Without Achieving a Deep Molecular Response: an Adaptative Trial Based on a Drop Loser Design
Essai Clinique (Centre hospitalier de Versailles)   06 août 2020
SPIRIT: A Phase III Prospective Randomized Comparison of Imatinib at a Dose of 400mg in Combination With Peg-Interferon-alpha2a (Peg-IFNa2a) or Cytarabine (Ara-C)Versus Imatinib at a Dose of 600mg Versus Imatinib a Dose of 400mg for Previously Untreated Chronic Myelogenous Leukemia (CML) in Chronic Phase
Essai Clinique (Novartis)   10 avril 2020